Table 3.
Univariate Analysis of Predictors for HT and Parenchymal Hematoma after Thrombectomy
| Comparison of any HT | Comparison of parenchymal HT | |||||
|---|---|---|---|---|---|---|
| Characteristic | No HT (n=55) | Any HT (n=50) | P | No PH (n=79) | Any PH (n=26) | P |
| Mean Age, years | 64.4±18.9 | 67.5±18.9 | 0.37 | 64.3±18.5 | 70.8±19.4 | 0.08 |
| Female, % | 61.8% (34/55) | 56.0% (28/50) | 0.55 | 65.8% (52/79) | 38.5% (10/26) | 0.02 |
| Cardioembolic stroke source | 58.2% (32/55) | 78.0% (39/50) | 0.03 | 64.6% (51/79) | 76.9% (20/26) | 0.34 |
| Hypertension | 61.8% (34/55) | 70.0% (35/50) | 0.38 | 62.0% (49/79) | 76.9% (20/26) | 0.23 |
| Diabetes mellitus | 16.4% (9/55) | 24.0% (12/50) | 0.33 | 19.0% (15/79) | 23.1% (6/26) | 0.78 |
| Hyperlipidemia | 27.3% (15/55) | 44.0% (22/50) | 0.08 | 31.6% (25/79) | 46.2% (12/26) | 0.24 |
| Coronary artery disease | 23.6% (13/55) | 28.0% (14/50) | 0.61 | 24.1% (19/79) | 30.8% (8/26) | 0.61 |
| Current smoking | 18.2% (10/55) | 16.0% (8/50) | 0.77 | 17.7% (14/79) | 15.4% (4/26) | >0.99 |
| Alcohol use | 9.1% (5/55) | 18.0% (9/50) | 0.18 | 11.4% (9/79) | 19.2% (5/26) | 0.49 |
| Atrial fibrillation | 32.7% (18/55) | 52.0% (26/50) | 0.05 | 36.7% (29/79) | 57.7% (15/26) | 0.07 |
| Peripheral vascular disorder | 5.5% (3/55) | 14.0% (7/50) | 0.25 | 10.1% (8/79) | 7.7% (2/26) | 0.99 |
| History of stroke or transient ischemic attack | 16.4% (9/55) | 12.0% (6/50) | 0.52 | 15.2% (12/79) | 11.5% (3/26) | 0.89 |
| Proximal stenosis | 7.3% (4/55) | 10.0% (5/50) | 0.88 | 6.3% (5/79) | 15.4% (4/26) | 0.30 |
| Glucose, mg/dL | 126±48.4 | 141±52.3 | 0.19 | 133±54.2 | 133±35.5 | 0.33 |
| Platelets count, ×103/μl | 229±66.3 | 211±69.4 | 0.05 | 227±71.2 | 204±54.8 | 0.13 |
| Hematocrit | 37.8±5.13 | 39.7±5.0 | 0.07 | 37.9±5.2 | 40.9±4.4 | 0.01 |
| Systolic blood pressure, mmHg | 156±32.1 | 161±32.7 | 0.48 | 155±31.8 | 169±32.3 | 0.06 |
| Diastolic blood pressure, mmHg | 82±17.3 | 86±19.8 | 0.32 | 82±17.5 | 91±20.3 | 0.03 |
| Premorbid antiplatelet use | 29.1% (16/55) | 34.0% (17/50) | 0.59 | 35.4% (28/79) | 19.2% (5/26) | 0.15 |
| Premorbid warfarin use | 7.3% (4/55) | 14.0% (7/50) | 0.26 | 6.3% (5/79) | 23.1% (6/26) | 0.04 |
| Baseline NIHSS score | 16.8±6.1 | 19.5±5.8 | 0.06 | 17.3±6.1 | 20.5±5.8 | 0.05 |
| Moderate or severe LA in DWM | 16.4% (9/55) | 34.0% (17/50) | 0.04 | 19.0% (15/79) | 42.3% (11/26) | 0.03 |
| Moderate or severe periventricular LA | 43.6% (24/55) | 38.0% (19/50) | 0.56 | 38.0% (30/79) | 50.0% (13/26) | 0.36 |
| Pure thrombectomy | 58.2% (32/55) | 54.0% (27/50) | 0.67 | 62.0% (49/79) | 38.5% (10/26) | 0.04 |
| IV tPA use | 23.6% (13/55) | 26.0% (13/50) | 0.82 | 22.8% (18/79) | 30.8% (8/26) | 0.44 |
| IA tPA use | 3.6% (2/55) | 12.0% (6/50) | 0.21 | 2.5% (2/79) | 23.1% (6/26) | 0.003 |
| Collateral flow grade 3 or 4 | 43.6% (24/55) | 42.0% (21/50) | 0.87 | 46.8% (37/79) | 30.8% (8/26) | 0.18 |
| Final TIMI II/III flow | 67.3% (37/55) | 82.0% (41/50) | 0.09 | 74.7% (59/79) | 73.1% (19/26) | >0.99 |
| Procedure-related vessel perforation | 3.6% (2/55) | 12.0% (6/50) | 0.21 | 3.8% (3/79) | 19.2% (5/26) | 0.03 |
| mRS ≤ 2 at discharge | 29.6% (16/54) | 20.4% (10/49) | 0.28 | 32.5% (25/77) | 3.8% (1/26) | 0.003 |
| In-hospital mortality | 9.3% (5/54) | 32.7% (16/49) | 0.003 | 10.4% (8/77) | 50.0% (13/26) | <0.001 |
| mRS at discharge | 3.0 (0–6) | 4.0 (1–6) | 0.003 | 3.0 (0–6) | 5.5 (1–6) | <0.001 |